Myotonic Dystrophy Type 1 (DM1) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Myotonic Dystrophy Type 1 (DM1) Emerging Therapy and TPP Insights

Thelansis’s “Myotonic Dystrophy Type 1 (DM1) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Myotonic Dystrophy Type 1 (DM1) Overview

Myotonic dystrophy type 1 (DM1), or Steinert disease, is a progressive, autosomal dominant multisystemic neuromuscular disorder caused by an unstable CTG trinucleotide repeat expansion in the 3′ untranslated region of the DMPK gene. This expansion leads to the nuclear retention of toxic transcript RNAs that sequester muscleblind-like (MBNL) splicing factors, inducing widespread embryonic spliceopathy across skeletal, cardiac, smooth muscle, and central nervous tissues. Patients clinically present with classic myotonia (delayed muscle relaxation), distal muscle weakness, ptosis, cataracts, early-onset balding, and severe hypoventilation. Crucially, conduction system disease creates lethal ventricular arrhythmias, making regular electrocardiographic or pacemaker surveillance mandatory. General anesthesia carries an unusually elevated risk of respiratory and cardiac collapse. Diagnosis is confirmed via targeted genetic molecular testing. Management in 2026 remains primarily supportive, utilizing mexiletine for disabling myotonia under strict cardiological monitoring, and nocturnal non-invasive ventilation for hypoventilation. However, the therapeutic landscape has transformed with advanced disease-modifying RNA-targeted candidates, including zeleciment basivarsen (DYNE-101), entering confirmatory pivotal phase 3 global evaluation.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Read more: Myotonic Dystrophy Type 1 (DM1) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026